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Abstract
Introduction: The significance of endothelial injury in children with the acute respiratory distress syndrome (ARDS)
has not been well studied. Plasma levels of soluble thrombomodulin (sTM), an endothelial surface protein involved
in coagulation, have been associated with endothelial injury. We hypothesized that elevated plasma sTM would
correlate with mortality and organ failure in children with ARDS.
Methods: We conducted a multicenter prospective observational study of pediatric patients with ARDS between
2008 and 2014. sTM was measured in plasma collected less than 24 hours from ARDS diagnosis. Outcomes were
intensive care unit mortality and organ dysfunction by pediatric logistic organ dysfunction scores. Logistic
regression was used to adjust for clinically relevant covariates.
Results: Plasma sTM was higher in patients with indirect lung injury compared to direct lung injury (100 ng/mL
vs. 86 ng/mL, p = 0.02). Increased sTM levels were correlated with more organ dysfunction in the entire study
population (Spearman’s rho = 0.37, p < 0.01). Overall mortality was 16 %. sTM levels were associated with increased
mortality in patients with indirect lung injury (OR 2.7 per log(sTM), p = 0.02). These relationships were independent
of age, oxygenation defect, or presence of acute kidney injury.
Conclusion: Elevated plasma sTM levels are associated with organ dysfunction in children with ARDS and with
higher mortality in children with indirect lung injury. These findings highlight the importance of endothelial injury
in children with ARDS and may guide the development of future therapies targeted toward endothelial
stabilization, repair, or functional replacement in this population.
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Introduction
Acute respiratory distress syndrome (ARDS) is a dis-
order historically consisting of hypoxemia accompanied
by bilateral pulmonary infiltrates and has been identified
as a major contributor to mortality in the pediatric inten-
sive care unit (PICU) population [1, 2]. ARDS involves
disruption of the integrity of both the pulmonary endothe-
lium and alveolar epithelium, leading to the development
of non-cardiogenic pulmonary edema [3]. While both epi-
thelial and endothelial surfaces are involved in the patho-
physiology of the disease, the location of initial insult has
classically been used to classify the disease as direct or in-
direct. Direct lung injury results primarily from injury to
the pulmonary epithelium, such as pneumonia or aspir-
ation. In contrast, indirect lung injury develops primarily
through damage to the pulmonary endothelium from ex-
trapulmonary sources of systemic inflammation such as
sepsis, trauma, or transfusions [4]. Though there is evi-
dence of endothelial injury in patients with ARDS of any
etiology, studies in adult patients with ARDS have demon-
strated evidence of increased endothelial injury among
those with indirect lung injury as compared to those with
direct lung injury [5–7]. In addition, endothelial dysfunc-
tion is associated with the development of multiple organ
dysfunction syndrome (MODS) [8], which is a major me-
diator of mortality in ARDS [9]. As such, assessment of
circulating measures of endothelial injury may improve
our understanding of the pathogenesis of ARDS in chil-
dren, provide a method to risk-stratify children with
ARDS, and provide supportive evidence to guide develop-
ment of future therapeutic interventions.
Thrombomodulin is a transmembrane protein present
on all endothelial surfaces and is highly expressed in
pulmonary alveolar capillaries [10]. It facilitates the
thrombin-mediated conversion of protein C to activated
protein C and has roles in coagulation, fibrinolysis, and
inflammation [11, 12]. During normal health, thrombo-
modulin (TM) sheds from the endothelial surface, and
soluble thrombomodulin (sTM) circulates at low levels
[12]. These circulating fragments have markedly attenu-
ated anticoagulant activity compared with cellular TM
or recombinant TM [13, 14]. In the presence of in-
flammation, neutrophil proteases increase the release
of sTM from the cell surface and thereby increase
circulating levels of sTM [15]. Studies in children
with meningococcal sepsis have documented this ef-
fect by demonstrating both depletion of endothelial
thrombomodulin and simultaneously increased plasma
sTM as compared to controls [16]. sTM levels are
similarly elevated in sepsis, disseminated intravascular
coagulation (DIC), vasculitis, venous thrombosis, and
trauma [17–19]. Experimental and clinical studies have
identified sTM as a marker of generalized endothelial in-
jury [20, 21].
sTM has been found to be elevated in the plasma and
alveolar edema fluid of adults with ARDS [22], and in-
creased plasma sTM levels are correlated with worse
clinical outcomes in adults with ARDS [23–25]. The role
of endothelial damage as measured by sTM in children
with ARDS and its relative importance in direct versus
indirect lung injury are unclear. We hypothesized that
sTM levels would be associated with mortality and organ
failure in a prospectively studied pediatric population
with ARDS and that the association might differ based
on the mechanism of lung injury.
Methods
Design and patient population
Data were collected between 2008 and 2014 as part of a
prospective, multicenter observational cohort of pediatric
acute lung injury. Patients were screened for eligibility
throughout their stay in five PICUs in California and
Wisconsin. Eligibility criteria included acute onset of
respiratory symptoms requiring non-invasive or invasive
positive pressure support. Patients met the American-
European Consensus Conference criteria (referred to in
the text as ARDS) [4]. Briefly, eligible patients had an
arterial partial pressure of oxygen (PaO2 mmHg) to
the fraction of inspired oxygen (FiO2) ratio (P/F ra-
tio) <300 mmHg and had new bilateral infiltrates on chest
radiography as judged by site investigators. Patients could
also become eligible based on pulse oximetry (SpO2) and
an SpO2/FiO2 ratio <253 when PaO2 values were not
available [26]. Patients were excluded if they were <30 days
of age, <36 weeks corrected gestational age, >18 years of
age, had a documented limitation of care order, were
wards of the state at the time of screening, or had been
enrolled in the cohort previously.
Ethics, consent and permissions
The institutional review board of the University of
California, San Francisco, CA, Oakland Children’s Hospital
and Research Center, Oakland, CA, Valley Children’s Hos-
pital, Madera, CA, Children’s Hospital Los Angeles, Los
Angeles, CA, and the University of Wisconsin, Madison,
WI reviewed and approved the collection of clinical data
and biological samples. Informed consent was obtained
from patients’ parents or legal guardians.
Data and sample collection
Demographics, and pre-existing medical conditions, as
documented in the medical record, were collected at
enrollment. The primary lung injury risk factor was
recorded as determined clinically by site investigators.
The lung injury group (direct vs. indirect) was then
assigned as previously described [4]. After enrollment,
daily data including vital signs, respiratory therapies, and
laboratory results were recorded. Pediatric risk of mortality
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(PRISM) III scores were calculated from these data [27].
Vasopressor use was recorded for any dose of one or more
of the following: dopamine, epinephrine, norepinephrine,
phenylephrine, dobutamine, or milrinone. Patients were
followed through hospital discharge. Plasma samples for
sTM assays were collected in EDTA tubes within 24 hours
of meeting study eligibility criteria. Plasma samples were
obtained only from indwelling catheters or during sched-
uled laboratory collections.
The primary outcome was death prior to intensive care
unit (ICU) discharge (ICU mortality). The secondary out-
come was the pediatric logistic organ dysfunction (PELOD)
score, which is a validated outcome measure of organ dys-
function in critically ill children [28]. The single worst
value for each component of the six-organ systems from
days 1-7, 14, 21, and 28 after study enrollment were used
in the calculation of the PELOD score. The number of
failing organ systems was defined as the number of organ
systems with a PELOD subscore ≥1 [28].
Soluble thrombomodulin assay
sTM was measured in plasma samples using two-
antibody sandwich enzyme-linked immunosorbent as-
says (Asserachrom Thrombomodulin assay, Diagnostica
Stago, Parsippany, NJ, USA). Samples were assayed in
duplicate according to the manufacturer’s protocol and
the mean value used for analysis. Samples were used for
analysis if the variance between duplicate sTM assays
was ≤15 %.
Statistical analysis
Normally distributed continuous data are reported as
mean and standard deviation, and were compared by t
test. Non-normally distributed, skewed data are reported
as median and interquartile range (IQR), and were
compared by the Mann–Whitney U test. Cuzick’s
non-parametric test of trend was used to assess for mono-
tonic trends across ordered groups [29]. Non-normally dis-
tributed, skewed variables were log-transformed for use in
parametric tests and for graphical representation as indi-
cated. Categorical variables were analyzed by the chi square
(χ2) test. We used Spearman rank correlation coefficients
(rho) to assess and test relationships between variables
without assuming normal distributions. We used logistic
regression models to quantify the relationships between
sTM and mortality and to adjust for covariates. Initially, we
assessed the effect of site on the analysis by including site
as a random intercept in a mixed effects logistic analysis.
The estimated variance of the random intercept was ex-
tremely small, consistent with there being no site effect.
We therefore used standard logistic regression models
for the remainder of the analysis. In view of our sam-
ple size we used bivariable models to adjust for one
covariate at a time. The Pearson chi square test was
used to assess the goodness of fit (GOF) of the data
to a logistic model.
We used linear regression analysis to quantify the rela-
tionship between sTM and PELOD and to adjust for
clinically significant covariates. We adjusted for clinically
significant covariates such as age, PRISM III, P/F ratio,
and the presence of acute kidney injury (AKI). These
covariates were chosen because sTM levels have been
reported to vary with age [30], to avoid confounding by
the severity of illness and initial lung injury, and AKI
was included because sTM is known to be primarily ex-
creted via the kidneys [14]. Due to the small numbers of
deaths, the adjusted logistic models for mortality each
only included a single potential confounding variable.
Patients were deemed to have AKI if one or more of the
following criteria were present: urine output <0.5 mL/
kg/h, estimated glomerular filtration rate <50 mL/min/
1.73 m2 body surface area, or receipt of hemodialysis
[31]. Receiver operator characteristic curve analysis was
used to assess the discrimination of sTM for mortality.
Statistical analysis was carried out using Stata 13 (Stata
Corporation, College Station, TX, USA).
Results
Study population
There were 308 patients enrolled during the study period,
of whom 243 had plasma samples available for sTM ana-
lysis and formed the study population. There were 65 pa-
tients who did not have adequate samples collected for
analysis due to absence of indwelling catheters and/or lack
of scheduled laboratory collection within the first 24 hours
after ARDS diagnosis. Baseline characteristics of the study
population are shown in Table 1. Demographic character-
istics including age, sex, race/ethnicity, lung injury risk
factors, previous medical conditions, and pediatric risk of
mortality scores were not statistically different between
those patients who did and did not have sTM measure-
ments as shown in Table S1 (see Additional file 1). Mortal-
ity for patients with sTM measurements was 16 %
compared with 9 % for those without sTM measurements,
though this difference was not statistically significant
(p = 0.17). Patients with sTM measurements had higher
rates of vasopressor use and progressed to have higher
PELOD scores as shown in Additional file 1, Table S1.
Patients with indirect lung injury were older than pa-
tients with direct lung injury (8.3 vs. 5.9 years, p <0.01).
Indirect lung injury patients also had higher cumulative
rates of vasopressor use (55 % vs. 38 %, p = 0.01). Other
baseline metrics were similar between the two groups
(Table 1).
Mortality and PELOD score
The overall mortality in the study population was 16 %.
Mortality in the indirect lung injury group was 18 %
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compared with 15 % in the direct group, though this
difference was not significant (p = 0.53). PELOD scores
ranged from 0 to 61 (median 20) and were similar be-
tween the two lung injury groups (p = 0.12) as shown in
Table 1.
sTM levels are associated with mortality only with indirect
lung injury
The median sTM level among the entire cohort was
93 ng/mL (IQR 57–138). There was no significant dif-
ference in sTM levels between survivors (92 ng/mL
(IQR 54–135)) and non-survivors (100 ng/mL (IQR 74–
160)) (p = 0.10). However, upon stratification by the type
of lung injury sTM levels were significantly elevated in
the indirect lung injury group (100 ng/mL (IQR 68–154))
compared with the direct lung injury group (86 ng/mL
(IQR 51–128)) (p = 0.02) (Figure S1, Additional file 2).
Within the indirect lung injury group sTM levels were sig-
nificantly elevated among non-survivors (149 ng/mL (IQR
87–223)) compared with survivors (96 ng/mL (IQR 63–
142)) (p = 0.02) (Fig. 1). This difference was not present
within the direct lung injury group (p = 0.88). We carried
out further analysis of the relationship between sTM and
mortality among those with indirect lung injury. On logis-
tic regression analysis within the indirect lung injury
group the odds of death were 2.7 times higher for each
natural log increase in sTM (95 % CI 1.2–6.1, p = 0.02).
After performing a goodness-of-fit analysis we did not
detect a departure from what would be expected if the
data followed a logistic model (p = 0.55) (Table 2). This as-
sociation remained significant after adjustment in bivari-
able models for age, presence of acute kidney injury or the
P/F ratio (Table 2). After adjustment for initial severity of
illness by the PRISM III score the independent association
between sTM and mortality was no longer present, but
the magnitude of the relationship remained similar (odds
ratio (OR) 2.4 95 % CI 0.90–6.4, p = 0.08). There was a
statistically significant interaction between the type of
lung injury (direct vs. indirect) and thrombomodulin
levels (p = 0.06). For receiver operator characteristic
analysis of the relationship between sTM and mortality
in indirect injury the area under the curve was 0.68
(95 % CI 0.54–0.82) (Figure S2, Additional file 2). Because
the relationship between sTM and mortality may be non-
linear, we also assessed mortality after stratification of the
indirect lung injury group into tertiles (1st: 23–78 ng/mL,
2nd: 79–138 ng/mL, 3rd: 138–752 ng/mL) of sTM levels.
In this analysis there was a significant stepwise increase
in mortality with increasing sTM tertiles (p = 0.02)
(Fig. 2).
sTM levels are associated with organ dysfunction
PELOD scores were then compared to sTM levels. In the
entire cohort, there was significant positive correlation be-
tween sTM and PELOD (Spearman’s rho = 0.37, p <0.01).
This correlation was maintained within the direct
Table 1 Baseline characteristics and outcomes for the study population
All patients (n = 243) Direct injury (n = 148) Indirect injury (n = 95) P valuea
Age, years 6.8 ± 6.0 5.9 ± 5.8 8.3 ± 5.9 <0.01
Male sex, n (%) 136 (56) 87 (59) 49 (52) 0.27
Caucasian, n (%) 152 (62) 92 (62) 60 (63) 0.88
Hispanic/Latino ethnicity, n (%) 92 (38) 62 (42) 30 (32) 0.11
Lung injury risk factor, n (%)
Pneumonia 135 (56) 135 (92) 0
Aspiration 9 (4) 9 (6) 0
Sepsis 56 (23) 0 56 (59)
Trauma 13 (5) 0 13 (14)
Multiple transfusions 7 (3) 0 7 (7)
Otherb 21 (9) 2 (1) 19 (20)
Previous medical conditions, n (%)
None 84 (34) 46 (31) 38 (40) 0.15
Malignancy or bone marrow transplant 39 (16) 26 (18) 13 (14) 0.42
Vasopressor usec, n (%) 108 (45) 56 (38) 52 (55) 0.01
PRISM IIId raw score, median 12 (6-20) 12 (6-18) 13 (7-21) 0.11
PELOD (IQR) 20 (11, 30) 20 (11, 30) 21 (11, 31) 0.12
Mortality, n (%) 39 (16) 22 (15) 17 (18) 0.53
aP-value represents comparison between direct and indirect lung injury groups. bOthers include: pancreatitis, leukemia, post-cardiopulmonary bypass, vascular
occlusive disease, hepatic failure. cVasopressor use at any point during the study period. dPRISM III: pediatric risk of mortality
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(rho = 0.33, p <0.01) and indirect (rho = 0.42, p <0.01)
lung injury groups. The association between sTM and
PELOD within the entire cohort remained significant
using linear regression to model adjustment for age,
P/F ratio, and presence of AKI (adjusted coefficient
3.3, 95 % CI 0.65–5.9, p = 0.02). PELOD was then
stratified by tertile of sTM within the entire cohort.
There was a stepwise increase in PELOD score with
each increasing tertile of sTM (p <0.01) (Figure S3,
Additional file 2). This association between elevated
sTM levels and PELOD persisted when the cohort was
stratified by type of lung injury (Figure S4, Additional
file 2). We also tested whether sTM levels were asso-
ciated with the number of non-pulmonary organ sys-
tem failures. sTM levels increased when stratified by
increasing numbers of failing non-pulmonary organ sys-
tems (p <0.001) (Fig. 3). This association remained signifi-
cant upon stratification by mechanism of lung injury
(p <0.001 for each of direct and indirect lung injury)
(Figure S5, Additional file 2). We also tested this as-
sociation after removal of the renal organ system from the
model to account for potential confounding related to
sTM clearance changes in AKI, and it remained significant
(p = 0.002 for direct lung injury and p <0.001 for indirect
lung injury).
Discussion
In this study we found that (1) elevated plasma sTM
levels within 24 hours of diagnosis in children with
ARDS are associated with organ dysfunction, (2) ele-
vated plasma sTM is associated with higher mortality
among patients with indirect lung injury, and (3) sTM
levels are elevated in indirect lung injury when com-
pared with direct lung injury. These findings emphasize
the importance of endothelial injury among pediatric pa-
tients with ARDS, especially in patients with an indirect
mechanism of lung injury.
Table 2 Estimated odds ratios assessing the association of
soluble thrombomodulin (sTM) levels with mortality in indirect
lung injury
Odds ratio 95 % Confidence interval P value
Log sTM 2.7 1.2-6.1 0.02
Bivariable regressiona
Log sTM 2.7 1.2-6.1 0.02
Age, years 1.0 0.91-1.1 0.95
Bivariable regressionb
Log sTM 2.5 1.03-6.2 0.04
Acute kidney injury 1.2 0.34-4.2 0.8
Bivariable regressionc
Log sTM 2.7 1.1-6.6 0.04
P/F ratio 0.99 0.98-1.0 0.1
Bivariable regressiond
Log sTM 2.4 0.9-6.4 0.08
PRISM III raw score 1.0 0.96-1.1 0.5
aN = 95, goodness of fit (GOF) p value = 0.52. bN = 95, GOF p value = 0.52. cN = 89,
GOF p value = 0.29. dN = 90, GOF p value = 0.54. P/F ratio of arterial partial















Survivors Non−Survivors Survivors Non−Survivors
Fig. 1 Comparison of soluble thrombomodulin (sTM) levels by mechanism of lung injury and mortality. Box plots comparing log-transformed
plasma sTM concentrations in survivors (dark gray) (n = 126 for direct lung injury, n = 78 for indirect lung injury) to non-survivors (light gray)
(n = 22 for direct lung injury, n = 17 for indirect lung injury), stratified by mechanism of lung injury. sTM concentrations were elevated in
non-survivors within the indirect lung injury group but not within the direct lung injury group: *p = 0.9, **p = 0.02
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The findings are consistent with the need for pro-
longed respiratory support [24] and increased mortal-
ity with elevated plasma sTM among adult patients
from the ARDS network studies [25]. The findings
are also consistent with studies that reported elevated
plasma sTM in pediatric sepsis [16, 32] and associa-
tions between plasma sTM and sepsis-related mortal-
ity and organ dysfunction in adults [33]. However, the
finding in our cohort that organ dysfunction scores
also correlate with plasma sTM levels in direct lung
injury implies that the relationship is not restricted to
septic patients.
Elevated plasma sTM early in the course of the ARDS
disease process provides a potential surrogate measurement
for the degree of endothelial damage. This is supported by
the location of thrombomodulin on the endothelial cell
membrane and experimental evidence demonstrating that
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Tertile of Soluble Thrombomodulin (Indirect) (ng/mL)
Fig. 2 Mortality within the indirect lung injury group (n = 95), stratified by increasing tertiles of soluble thrombomodulin (sTM). sTM ranges for
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Number of Non−Pulmonary Organ Failures
Fig. 3 Number of failing non-pulmonary organ systems as a function of soluble thrombomodulin (sTM) level. Log-transformed sTM levels among
the entire study population stratified by the number of failing non-pulmonary organ systems as assessed by pediatric logistic organ dysfunction:
n = 39 for no organ systems, n = 86 for one system, n = 57 for two systems, n = 42 for three systems. Individuals with four or more failing
non-pulmonary organ systems are depicted as a single group (n = 19). sTM levels increase with increasing numbers of failing organ systems
(p <0.01 across all strata)
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inflammation [20]. In addition, plasma sTM levels correl-
ate with the concentration of circulating endothelial cells,
which is a metric of endothelial damage [21]. Previous
studies of adult patients have also found evidence that
endothelial activation and injury are important in the
pathogenesis of ARDS. Von willebrand factor (VWF), an-
other potential marker of endothelial dysfunction pro-
duced by endothelial cells and platelets, is elevated in
patients with non-pulmonary sepsis who go on to develop
ARDS [34]. VWF early in the course of ARDS has also
been associated with mortality and increased rates of
organ failure in adults and a small study in children
[35, 36]. In another adult study increased plasma
angiopoietin 2, a marker of endothelial dysfunction and
vascular permeability, was associated with increased mor-
tality and fewer ventilator-free-days [37]. The outcome of
our study is consistent with these findings and helps ex-
tend the importance of endothelial injury and dysfunction
in ARDS to pediatric populations.
Another possible mechanism for the observed associ-
ation between elevated plasma sTM and adverse clinical
outcomes is through increased intravascular thrombosis,
leading to impaired microcirculation and the development
of organ dysfunction. Decreased intact cellular thrombo-
modulin in the setting of inflammation [16] and the obser-
vation of relatively decreased anticoagulant activity of its
soluble form [13] suggest that patients with elevated
plasma sTM are at increased risk of organ injury. Studies
of ARDS in animal models and human subjects have sug-
gested that pulmonary coagulopathy plays a significant role
in the pathobiology of this disease and its associated co-
morbidities [38]. Relative deficiencies in proteins such as
protein C, antithrombin, tissue factor pathway inhibitor,
plasminogen activator inhibitor 1, and thrombomodulin
have been implicated in this disruption of the normal bal-
ance of procoagulant and anticoagulant forces [38, 39].
The nature of this mechanism suggests that soluble throm-
bomodulin may be an important mediator of disease in
ARDS and an early marker of disease severity.
Despite biological plausibility and promising results in
animal models of sepsis and acute lung injury, repletion of
natural anticoagulant proteins has thus far shown limited
success in human trials [38]. However, none of these trials
used biological markers to target these therapies to spe-
cific patient populations. Clinical trials have investigated
the use of recombinant soluble thrombomodulin therapy
in sepsis, DIC, and ARDS [40, 41], though no conclusive
pediatric data are available as of yet. These trials did not
report pre-treatment sTM levels or use plasma sTM as a
basis for targeted therapy with recombinant TM. The re-
sults suggest that pediatric patients with ARDS, especially
sicker patients with elevated plasma levels of sTM, may be
potential candidates for future studies of recombinant
thrombomodulin replacement therapy.
The primary strengths of this study are the relatively
large size of our pediatric ARDS cohort and the pro-
spective collection of biological samples, which is
unusual in this population. The absolute numbers of
patients and outcome events also limited our analysis,
especially the ability to adjust for multiple potential con-
founders within a single logistic regression model. We
therefore used multiple bivariable models to adjust for
one potential confounder at a time. After adjustment for
the initial severity of illness by PRISM III the association
between sTM and mortality was no longer statistically
significant in our logistic model. The magnitude of the
association was only slightly attenuated, and the loss of
significance may have been related to inadequate sample
size. However, our population is reflective of the rela-
tively low frequency of ARDS and decreasing mortality
[2] from ARDS in children, and nonetheless we were
able to identify significant association between sTM and
mortality among patients with indirect lung injury. An-
other limitation is our inability to obtain plasma samples
for analysis of the entire cohort. However, the patients
without plasma samples had less organ dysfunction
and lower absolute mortality, indicating that those pa-
tients were less severely ill and consistent with the fact
that they did not require indwelling central lines or arter-
ial lines from which to draw samples. This may limit
applicability of our findings to more critically ill ARDS
patients.
Conclusions
In summary elevated soluble thrombomodulin, when
measured in children early in the course of ARDS, is
associated with increased organ dysfunction and also
is associated with increased odds of mortality among
children with an indirect mechanism of lung injury.
These findings should be validated in additional pop-
ulations, but they provide evidence of the important
role of the magnitude of endothelial injury in determining
outcomes from pediatric ARDS. Future interventions tar-
geted toward endothelial stabilization, repair, or functional
supplementation may benefit this population.
Key messages
 sTM, a marker of endothelial injury, is elevated in
children with ARDS due to indirect lung injury
relative to those with direct lung injury
 sTM levels are independently associated with
increased mortality in children with ARDS due to
indirect lung injury when measured at the time of
ARDS diagnosis
 sTM levels are associated with increasing organ
failure scores and number of failing organ systems
in children with ARDS
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